BACKGROUND: HIV infection increases the risk of malaria infection in pregnant women. Antibodies to variant surface antigens (VSA) on infected erythrocytes might protect against malaria in pregnancy. We postulated that HIV-induced impairment of humoral immunity to VSA mediates the increased susceptibility to malaria. METHODS: We compared serum concentrations of antibodies to VSA by flow cytometry or agglutination, and to merozoite proteins AMA-1 and MSP119 by ELISA, in 298 pregnant Malawian women, and related the findings to malaria and HIV infection, CD4-positive T-cell count, and HIV-1 viral load. FINDINGS: Concentrations of IgG to placental type VSA were lower in HIV-infected women than in HIV-uninfected women (median 8 units [IQR 4-23] vs 20 [12-30]; p<0.0001), among women with malaria (p=0.009) and those without malaria (p=0.0062). The impairment was greatest in first pregnancy. Agglutinating antibodies to placental VSA were present in a lower proportion of HIV-infected than HIV-uninfected women (58 [35.1%] of 165 vs 50 [53.8%] of 93, p<0.001). The degree of antibody binding by flow cytometry was correlated with CD4-positive T-cell count (r=0.16, p=0.019) and inversely with HIV-1 viral load (r=-0.16, p=0.030). Concentrations of antibodies to AMA-1 were lower in HIV infection (p<0.0001) but were not correlated with CD4-positive T-cell count or viral load. Responses to MSP119 were little affected by HIV infection. In multivariate analyses, HIV was negatively associated with amount of antibody to both VSA and AMA-1 (p<0.001 for each) but not MSP119. INTERPRETATION: HIV infection impairs antimalarial immunity, especially responses to placental type VSA. The impairment is greatest in the most immunosuppressed women and could explain the increased susceptibility to malaria seen in pregnant women with HIV infection.
BACKGROUND:HIV infection increases the risk of malaria infection in pregnant women. Antibodies to variant surface antigens (VSA) on infected erythrocytes might protect against malaria in pregnancy. We postulated that HIV-induced impairment of humoral immunity to VSA mediates the increased susceptibility to malaria. METHODS: We compared serum concentrations of antibodies to VSA by flow cytometry or agglutination, and to merozoite proteins AMA-1 and MSP119 by ELISA, in 298 pregnant Malawian women, and related the findings to malaria and HIV infection, CD4-positive T-cell count, and HIV-1 viral load. FINDINGS: Concentrations of IgG to placental type VSA were lower in HIV-infectedwomen than in HIV-uninfectedwomen (median 8 units [IQR 4-23] vs 20 [12-30]; p<0.0001), among women with malaria (p=0.009) and those without malaria (p=0.0062). The impairment was greatest in first pregnancy. Agglutinating antibodies to placental VSA were present in a lower proportion of HIV-infected than HIV-uninfectedwomen (58 [35.1%] of 165 vs 50 [53.8%] of 93, p<0.001). The degree of antibody binding by flow cytometry was correlated with CD4-positive T-cell count (r=0.16, p=0.019) and inversely with HIV-1 viral load (r=-0.16, p=0.030). Concentrations of antibodies to AMA-1 were lower in HIV infection (p<0.0001) but were not correlated with CD4-positive T-cell count or viral load. Responses to MSP119 were little affected by HIV infection. In multivariate analyses, HIV was negatively associated with amount of antibody to both VSA and AMA-1 (p<0.001 for each) but not MSP119. INTERPRETATION:HIV infection impairs antimalarial immunity, especially responses to placental type VSA. The impairment is greatest in the most immunosuppressed women and could explain the increased susceptibility to malaria seen in pregnant women with HIV infection.
Authors: Atis Muehlenbachs; Michal Fried; Rose McGready; Whitney E Harrington; Theonest K Mutabingwa; François Nosten; Patrick E Duffy Journal: J Infect Dis Date: 2010-10-07 Impact factor: 5.226
Authors: Obinna N Nnedu; Michael P O'Leary; Daniel Mutua; Beth Mutai; Mina Kalantari-Dehaghi; Al Jasinskas; Rie Nakajima-Sasaki; Grace John-Stewart; Phelgona Otieno; Xiaowu Liang; John Waitumbi; Francis Kimani; David Camerini; Philip L Felgner; Judd L Walson; Adam Vigil Journal: Proteomics Clin Appl Date: 2011-12 Impact factor: 3.494
Authors: Lea Barfod; Tina Dobrilovic; Pamela Magistrado; Pongsak Khunrae; Firmine Viwami; Jonas Bruun; Madeleine Dahlbäck; Nadia L Bernasconi; Michal Fried; Davis John; Patrick E Duffy; Ali Salanti; Antonio Lanzavecchia; Chwee Teck Lim; Nicaise Tuikue Ndam; Matthew K Higgins; Lars Hviid Journal: J Immunol Date: 2010-11-15 Impact factor: 5.422
Authors: Ricardo Ataíde; Wina Hasang; Danny W Wilson; James G Beeson; Victor Mwapasa; Malcolm E Molyneux; Steven R Meshnick; Stephen J Rogerson Journal: PLoS One Date: 2010-05-25 Impact factor: 3.240
Authors: Patrick M Newman; Humphrey Wanzira; Gabriel Tumwine; Emmanuel Arinaitwe; Sarah Waldman; Jane Achan; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Tamara D Clark; Deborah Cohan Journal: Malar J Date: 2009-11-14 Impact factor: 2.979